SCHEMBL31449583

SCHEMBL31449583

COc1cc(-c2ccccc2Cl)c(Br)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OXTR P30559 1/20 0.41
AVPR1A P37288 1/20 0.41
HSD11B1 P28845 1/20 0.39
KMT2A Q03164 2/20 0.38
POLB P06746 1/20 0.38
GABRP O00591 1/20 0.38
GABRD O14764 1/20 0.38
GABRA1 P14867 1/20 0.38
GABRB1 P18505 1/20 0.38
GABRG2 P18507 1/20 0.38
GABRB3 P28472 1/20 0.38
GABRA5 P31644 1/20 0.38
GABRA3 P34903 1/20 0.38
GABRA2 P47869 1/20 0.38
GABRB2 P47870 1/20 0.38
GABRA4 P48169 1/20 0.38
GABRE P78334 1/20 0.38
GABRA6 Q16445 1/20 0.38
GABRG1 Q8N1C3 1/20 0.38
GABRG3 Q99928 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20532496 0.79 GABRG2 (0.41) KMT2AGABRPGABRDGABRA1GABRB1
SCHEMBL5782857 0.78 HSD11B1 (0.40) HSD11B1KMT2APOLBKDM4EALDH1A1
SCHEMBL31450014 0.78 HSD11B1 (0.40) HSD11B1KMT2APOLBKDM4EALDH1A1
SCHEMBL31449953 0.78 TSHR (0.41) OXTRAVPR1AHSD11B1KMT2APOLB
SCHEMBL676674 0.76 NNMT (0.37) KMT2AGABRPGABRDGABRA1GABRB1
SCHEMBL31449934 0.74 TSHR (0.41) OXTRAVPR1AHSD11B1KMT2ATSHR
SCHEMBL31450071 0.74 L3MBTL1 (0.41) OXTRAVPR1AKMT2APOLBKDM4E
SCHEMBL20686294 0.73 MEN1 (0.35) KMT2ATSHRALOX15SMN1; SMN2L3MBTL1
SCHEMBL31449884 0.72 MEN1 (0.47) HSD11B1KMT2ATSHRCYP1A2CYP3A4
SCHEMBL13575394 0.72 OXTR (0.53) OXTRAVPR1AKDM4ESMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026721-A1 COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K VIVIDION THERAPEUTICS, INC. 2025-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026721-A1 COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K KRAS, HRAS, NRAS OXTR 4498/4885AVPR1A 4272/4885HSD11B1 3009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.